Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 35.95
+0.45 (1.27%)
Aug 19, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 9.41 billion as of August 18, 2026. Its market cap has decreased by -29.49% in one year.
Market Cap
9.41B
Enterprise Value
10.64B
Revenue
483.94M
Ranking
n/a
PE Ratio
n/a
Stock Price
35.95
ChartMarket Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 9.41B, a decrease of -43.91%. That is a compound annual growth rate of -5.11%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 19, 2026 | 9.41B | -35.41% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| ACRO Biomedical | 13.32B |
| Gongwin Biopharm Holdings | 11.94B |
| AP Biosciences | 9.84B |
| Polaris Group | 9.29B |
| TCM Biotech International | 8.80B |
| PharmaEngine | 8.48B |
| Locus Cell | 7.60B |
| Adimmune | 7.27B |